These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12879292)

  • 1. Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use.
    Bouet-Toussaint F; Patard JJ; Gervais A; Genetet N; de la Pintière CT; Rioux-Leclercq N; Toutirais O; Thirouard AS; Ramée MP; Catros-Quemener V
    Cancer Immunol Immunother; 2003 Nov; 52(11):699-707. PubMed ID: 12879292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
    Kurokawa T; Oelke M; Mackensen A
    Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells.
    Gervais A; Bouet-Toussaint F; Toutirais O; De La Pintiere CT; Genetet N; Catros-Quemener V
    Anticancer Res; 2005; 25(3B):2177-85. PubMed ID: 16158961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.
    Zhou J; Weng D; Zhou F; Pan K; Song H; Wang Q; Wang H; Wang H; Li Y; Huang L; Zhang H; Huang W; Xia J
    Cancer Immunol Immunother; 2009 Oct; 58(10):1587-97. PubMed ID: 19221746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk.
    Cabillic F; Bouet-Toussaint F; Toutirais O; Rioux-Leclercq N; Fergelot P; de la Pintière CT; Genetet N; Patard JJ; Catros-Quemener V
    Clin Exp Immunol; 2006 Dec; 146(3):518-23. PubMed ID: 17100773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
    Gigante M; Mandic M; Wesa AK; Cavalcanti E; Dambrosio M; Mancini V; Battaglia M; Gesualdo L; Storkus WJ; Ranieri E
    J Immunother; 2008 Apr; 31(3):254-62. PubMed ID: 18317362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma.
    Hinkel A; Tso CL; Gitlitz BJ; Neagos N; Schmid I; Paik SH; deKernion J; Figlin R; Belldegrun A
    J Immunother; 2000 Jan; 23(1):83-93. PubMed ID: 10687141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human accessory cells activate fresh, normal, tumor-distant T lymphocytes but not tumor-infiltrating T lymphocytes to lyse autologous tumor cells in a primary cytotoxic T lymphocyte assay in renal cell carcinoma.
    Kramer G; Steiner GE; Paiha S; Handisurya A; Djavan B; Mallone R; Marberger M
    Eur Urol; 2001 Oct; 40(4):427-33. PubMed ID: 11713398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical course and immune response of a renal cell carcinoma patient to adoptive transfer of autologous cytotoxic T lymphocytes.
    Kawai K; Saijo K; Oikawa T; Morishita Y; Noguchi M; Ohno T; Akaza H
    Clin Exp Immunol; 2003 Nov; 134(2):264-9. PubMed ID: 14616786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
    Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antitumor response induced by vaccine of autologous dendritic/tumor fusion cells against renal cell].
    Zhou J; Xia JC; Wang H; Wang QJ; Huang LX; Li YQ; Chen SP; Zhou FJ
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):411-4. PubMed ID: 17974271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
    Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
    J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
    Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
    Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency.
    Gervais A; Levêque J; Bouet-Toussaint F; Burtin F; Lesimple T; Sulpice L; Patard JJ; Genetet N; Catros-Quemener V
    Breast Cancer Res; 2005; 7(3):R326-35. PubMed ID: 15987427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
    Märten A; Renoth S; Heinicke T; Albers P; Pauli A; Mey U; Caspari R; Flieger D; Hanfland P; Von Ruecker A; Eis-Hübinger AM; Müller S; Schwaner I; Lohmann U; Heylmann G; Sauerbruch T; Schmidt-Wolf IG
    Hum Gene Ther; 2003 Mar; 14(5):483-94. PubMed ID: 12691613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine.
    Gigante M; Blasi A; Loverre A; Mancini V; Battaglia M; Selvaggi FP; Maiorano E; Napoli A; Castellano G; Storkus WJ; Gesualdo L; Ranieri E
    Mol Immunol; 2009 Feb; 46(5):893-901. PubMed ID: 19041139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
    Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.